Seeking Alpha

Citigroup says to buy the dip in Bristol-Myers (BMY +1.5%). The firm believes the FDA's complete...

Citigroup says to buy the dip in Bristol-Myers (BMY +1.5%). The firm believes the FDA's complete response letter on Eliquis will be resolved quickly and should delay the U.S. launch of the drug by only by a couple of months. The delay won't significantly change its estimates, and the it maintains its a $40 price target on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs